HR Execs on the Move

Acceleron Pharma

www.acceleronpharma.com

 
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details
Deirdre Rooks
Sr. Director, R&D Quality Assurance Profile

Similar Companies

Adcentrx Therapeutics

Adcentrx Therapeutics is a biotechnology company focused on accelerating breakthroughs in protein conjugate therapeutic development for cancer and other life-threatening diseases.

Avail Scientific

Avail Scientific is working to facilitate a medical and social revolution of the current pharmacological therapies for addiction and the underlying causes by providing evidence-based diagnostic and data acquisition programs. These substances can be used as both treatment for addiction and as preventative therapy by addressing the health challenges underlying substance abuse. We are building a platform to both educate and equip healthcare professionals with the data to use these therapeutic tools efficiently. Our objective is to treat this medical condition and prove out rehabilitation and preventative therapy programs with our partners in healthcare communities, both local and globally. Avail Scientific is positioned to become a global leader in eliminating the needless suffering that surrounds addiction and mental health issues by providing effective data and patient monitoring to validate their efficacy.

BBRAUN Medical

BBRAUN Medical is a Cleveland, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lynxcom Partners

Lynxcom Partners is a Del Mar, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Revance

Revance Therapeutics is a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, including muscle movement disorders and pain. The company`s lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines, cervical dystonia and plantar fasciitis with the potential to be the first long-acting neuromodulator. Revance has developed a proprietary, stabilizing excipient peptide technology designed to create novel, differentiated therapies. The company has a comprehensive pipeline based upon its peptide technology, including injectable and topical formulations of daxibotulinumtoxinA.